6-Month Versus 12-Month Dual-Antiplatelet Therapy Following Long Everolimus-Eluting Stent Implantation

This publication has 28 references indexed in Scilit:

• Short- Versus Long-Term Duration of Dual-Antiplatelet Therapy After Coronary Stenting
  Circulation, 2012
• Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials
  European Heart Journal, 2012
• Six-Month Versus 12-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents
  Circulation, 2012
• 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention
  JACC, 2011
• Impact of the Everolimus-Eluting Stent on Stent Thrombosis
  JACC, 2011
• Predictors of death or myocardial infarction, ischaemic-driven revascularisation, and major adverse cardiovascular events following everolimus-eluting or paclitaxel-eluting stent deployment: pooled analysis from the SPIRIT II, III, IV and COMPARE trials
  EuroIntervention, 2011
• The Relationship and Threshold of Stent Length With Regard to Risk of Stent Thrombosis After Drug-Eluting Stent Implantation
  JACC: Cardiovascular Interventions, 2010
• Incidence and Predictors of Drug-Eluting Stent Thrombosis During and After Discontinuation of Thienopyridine Treatment
  Circulation, 2007
• Clinical End Points in Coronary Stent Trials
  Circulation, 2007
• Assessment of Bleeding Events in Clinical Trials—Proposal of a New Classification
  The American Journal of Cardiology, 2007